JP2021522249A5 - - Google Patents
Info
- Publication number
- JP2021522249A5 JP2021522249A5 JP2020559472A JP2020559472A JP2021522249A5 JP 2021522249 A5 JP2021522249 A5 JP 2021522249A5 JP 2020559472 A JP2020559472 A JP 2020559472A JP 2020559472 A JP2020559472 A JP 2020559472A JP 2021522249 A5 JP2021522249 A5 JP 2021522249A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- 4alkyl
- substituted
- nhs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023149057A JP7660634B2 (ja) | 2018-04-25 | 2023-09-14 | Ｎｌｒｐ３修飾因子 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662240P | 2018-04-25 | 2018-04-25 | |
| US62/662,240 | 2018-04-25 | ||
| US201862764818P | 2018-08-16 | 2018-08-16 | |
| US62/764,818 | 2018-08-16 | ||
| US201962825044P | 2019-03-28 | 2019-03-28 | |
| US62/825,044 | 2019-03-28 | ||
| PCT/US2019/028823 WO2019209896A1 (en) | 2018-04-25 | 2019-04-24 | Nlrp3 modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149057A Division JP7660634B2 (ja) | 2018-04-25 | 2023-09-14 | Ｎｌｒｐ３修飾因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522249A JP2021522249A (ja) | 2021-08-30 |
| JP2021522249A5 true JP2021522249A5 (enExample) | 2022-04-25 |
| JP7351850B2 JP7351850B2 (ja) | 2023-09-27 |
Family
ID=66677224
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559472A Active JP7351850B2 (ja) | 2018-04-25 | 2019-04-24 | Ｎｌｒｐ３修飾因子 |
| JP2023149057A Active JP7660634B2 (ja) | 2018-04-25 | 2023-09-14 | Ｎｌｒｐ３修飾因子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149057A Active JP7660634B2 (ja) | 2018-04-25 | 2023-09-14 | Ｎｌｒｐ３修飾因子 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12037344B2 (enExample) |
| EP (2) | EP4353235A3 (enExample) |
| JP (2) | JP7351850B2 (enExample) |
| KR (1) | KR102711180B1 (enExample) |
| CN (2) | CN112074516A (enExample) |
| AU (1) | AU2019261582A1 (enExample) |
| BR (1) | BR112020021539A2 (enExample) |
| CA (1) | CA3097865A1 (enExample) |
| CL (1) | CL2020002719A1 (enExample) |
| CO (2) | CO2020013155A2 (enExample) |
| ES (1) | ES2971122T3 (enExample) |
| IL (1) | IL278173A (enExample) |
| MX (1) | MX2020011234A (enExample) |
| NZ (1) | NZ769136A (enExample) |
| PE (1) | PE20210160A1 (enExample) |
| SG (1) | SG11202010463TA (enExample) |
| TW (1) | TW202014420A (enExample) |
| WO (1) | WO2019209896A1 (enExample) |
| ZA (1) | ZA202007307B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4087842A1 (en) * | 2020-01-10 | 2022-11-16 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| AU2021254794A1 (en) * | 2020-04-16 | 2022-12-15 | Incyte Corporation | Fused tricyclic KRAS inhibitors |
| MX2022013637A (es) | 2020-04-30 | 2022-11-16 | Janssen Pharmaceutica Nv | Nuevos compuestos de triazinoindol. |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| AU2021279305A1 (en) * | 2020-05-28 | 2023-02-09 | Janssen Pharmaceutica Nv | Compounds |
| CN116390923B (zh) * | 2020-08-21 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
| US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
| EP3984535A1 (en) * | 2020-10-16 | 2022-04-20 | Albert-Ludwigs-Universität Freiburg | Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome |
| WO2022115377A1 (en) * | 2020-11-24 | 2022-06-02 | Amgen Inc. | Tricyclic carboxamide derivatives as prmt5 inhibitors |
| CN114539095A (zh) * | 2020-11-26 | 2022-05-27 | 乐凯化学材料有限公司 | 3-（4-羟基-3-甲氧基-苯基）-2-氰基-2-丙烯酸乙酯的制备方法 |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| MX2024000357A (es) | 2021-07-07 | 2024-02-12 | Incyte Corp | Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras). |
| WO2023287896A1 (en) | 2021-07-14 | 2023-01-19 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| CN117940120A (zh) * | 2021-07-16 | 2024-04-26 | 戴纳立制药公司 | 化合物、组合物和方法 |
| US12441742B2 (en) | 2021-08-31 | 2025-10-14 | Incyte Corporation | Naphthyridine compounds as inhibitors of KRAS |
| WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
| CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
| CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| WO2025190317A1 (en) * | 2024-03-13 | 2025-09-18 | National Institute Of Biological Sciences, Beijing | Urea compounds as nlrp3 agonists |
| WO2026006603A1 (en) * | 2024-06-26 | 2026-01-02 | Wisconsin Alumni Research Foundation | Tlr7/tlr8 agonists for use in trifunctional radiopharmaceutical compounds |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| US20090075980A1 (en) | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
| KR20060120069A (ko) | 2003-10-03 | 2006-11-24 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
| US20070259907A1 (en) | 2004-06-18 | 2007-11-08 | Prince Ryan B | Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
| US20080193468A1 (en) * | 2004-09-08 | 2008-08-14 | Children's Medical Center Corporation | Method for Stimulating the Immune Response of Newborns |
| US8378102B2 (en) | 2005-02-09 | 2013-02-19 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| JP2010535844A (ja) | 2007-08-14 | 2010-11-25 | ノバルティス アーゲー | Ｇａｂａアルファリガンドとしてのピラゾロキノリンおよびピラゾロナフチリジン誘導体 |
| US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| AU2012244549B2 (en) | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| SI2573073T1 (sl) | 2011-09-26 | 2015-02-27 | Sanofi | Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104418867B (zh) * | 2013-08-26 | 2016-12-28 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015095780A1 (en) | 2013-12-20 | 2015-06-25 | The University Of Kansas | Toll-like receptor 8 agonists |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN121243402A (zh) | 2014-07-09 | 2026-01-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1组合 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| WO2016199943A1 (en) | 2015-06-11 | 2016-12-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR20180040706A (ko) | 2015-09-01 | 2018-04-20 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도 |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| CN105523955B (zh) * | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN108029076B (zh) | 2016-02-02 | 2020-03-10 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| KR20180134395A (ko) | 2016-04-19 | 2018-12-18 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| US11344543B2 (en) | 2017-07-14 | 2022-05-31 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| KR102709679B1 (ko) | 2018-04-25 | 2024-09-26 | 바이엘 악티엔게젤샤프트 | 살충제로서의 신규 헤테로아릴-트리아졸 및 헤테로아릴-테트라졸 화합물 |
-
2019
- 2019-04-24 PE PE2020001652A patent/PE20210160A1/es unknown
- 2019-04-24 EP EP23211253.2A patent/EP4353235A3/en active Pending
- 2019-04-24 WO PCT/US2019/028823 patent/WO2019209896A1/en not_active Ceased
- 2019-04-24 US US17/049,612 patent/US12037344B2/en active Active
- 2019-04-24 SG SG11202010463TA patent/SG11202010463TA/en unknown
- 2019-04-24 CA CA3097865A patent/CA3097865A1/en active Pending
- 2019-04-24 NZ NZ769136A patent/NZ769136A/en unknown
- 2019-04-24 KR KR1020207033384A patent/KR102711180B1/ko active Active
- 2019-04-24 JP JP2020559472A patent/JP7351850B2/ja active Active
- 2019-04-24 ES ES19727780T patent/ES2971122T3/es active Active
- 2019-04-24 CN CN201980027881.7A patent/CN112074516A/zh active Pending
- 2019-04-24 CN CN202011468364.4A patent/CN112521387B/zh active Active
- 2019-04-24 AU AU2019261582A patent/AU2019261582A1/en not_active Abandoned
- 2019-04-24 BR BR112020021539-2A patent/BR112020021539A2/pt not_active IP Right Cessation
- 2019-04-24 EP EP19727780.9A patent/EP3784670B1/en active Active
- 2019-04-24 MX MX2020011234A patent/MX2020011234A/es unknown
- 2019-04-25 TW TW108114491A patent/TW202014420A/zh unknown
-
2020
- 2020-10-20 IL IL278173A patent/IL278173A/en unknown
- 2020-10-21 CO CONC2020/0013155A patent/CO2020013155A2/es unknown
- 2020-10-21 CL CL2020002719A patent/CL2020002719A1/es unknown
- 2020-10-21 CO CONC2021/0006672A patent/CO2021006672A2/es unknown
- 2020-11-24 ZA ZA2020/07307A patent/ZA202007307B/en unknown
-
2023
- 2023-09-14 JP JP2023149057A patent/JP7660634B2/ja active Active